AEGIS CAPITAL CORP.Cyngn Inc. • December 11th, 2023 • Services-computer programming services • New York
Company FiledDecember 11th, 2023 Industry JurisdictionThe purpose of this placement agent agreement (“Agreement”) Agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed fully marketed public offering (the “Placement”) by Cyngn Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its shares of Common Stock (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Cyngn Inc. • November 14th, 2023 • Services-computer programming services • New York
Company FiledNovember 14th, 2023 Industry JurisdictionThe purpose of this placement agent agreement (“Agreement”) Agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed fully marketed public offering (the “Placement”) by Cyngn Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its shares of Common Stock (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP. July __ 2023Clearmind Medicine Inc. • July 17th, 2023 • Pharmaceutical preparations • New York
Company FiledJuly 17th, 2023 Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Clearmind Medicine Inc. • April 6th, 2023 • Pharmaceutical preparations • New York
Company FiledApril 6th, 2023 Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
AEGIS CAPITAL CORP.Clearmind Medicine Inc. • March 27th, 2023 • Pharmaceutical preparations • New York
Company FiledMarch 27th, 2023 Industry JurisdictionThe purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by Clearmind Medicine Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of its common shares and warrants to purchase common shares (the “Securities”). The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.